Publications by authors named "David Marmolejo"

Claim this Profile
B
Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review.
Clara Salva de Torres, Ernesto Trallero-Araguas, David Marmolejo, José Maria Ucha Hermida, Nely Díaz Mejía

Crit Rev Oncol Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.
Dimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, Jacob B Leary, Dimitrios Makrakis, David Marmolejo

Clin Genitourin Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, Leonidas N Diamantopoulos, Thomas Enright, David Marmolejo

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.
Sara Arce-Gallego, Pablo Cresta Morgado, Luisa Delgado-Serrano, Sara Simonetti, Macarena Gonzalez, David Marmolejo

Cell Rep Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, Rafael Morales-Barrera, Francesco Grussu, David Marmolejo

Eur Urol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
Alberto Hernando-Calvo, Oriol Mirallas, David Marmolejo, Omar Saavedra, María Vieito

Oral Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias".
Guillermo Villacampa, Alberto Hernando-Calvo, Roger Berché, Omar Saavedra, David Marmolejo

Cancer Treat Rev· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease.
Cristina Suarez, David Marmolejo, Augusto Valdivia, Rafael Morales-Barrera, Macarena Gonzalez

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
David Humberto Marmolejo, Mark Yu Zheng Wong, Svetlana Bajalica-Lagercrantz, Marc Tischkowitz, Judith Balmaña

Eur J Med Genet· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort.
Susana Cedres, Juan-David Assaf, Patricia Iranzo, Ana Callejo, Nuria Pardo, David Marmolejo

Sci Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-to-date role of aflibercept in the treatment of colorectal cancer.
Nadia Saoudi Gonzalez, Francesc Salvà, Javier Ros, Iosune Baraibar, David Marmolejo

Expert Opin Biol Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients.
Ana Callejo, Joan Frigola, Patricia Iranzo, Caterina Carbonell, Nely Diaz, David Marmolejo

Cancers (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors.
Mar Riveiro-Barciela, Didac González-Sans, David Marmolejo, Maria-Teresa Salcedo, Eva Muñoz-Couselo

J Gastrointestin Liver Dis· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Grade I meningioma with disseminated bone disease: a rare clinical phenomenon.
Oriol Mirallas, David Marmolejo, Augusto Valdivia, Maria Vieito

BMJ Case Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis